The Landscape of Patient Access to Direct Acting Antivirals by Payer Within the United States Healthcare System

The Landscape of Patient Access to Direct Acting Antivirals by Payer Within the United States... Curr Hepatology Rep (2017) 16:192–197 DOI 10.1007/s11901-017-0359-5 HEPATITIS C (J AHN AND A ARONSOHN, SECTION EDITORS) The Landscape of Patient Access to Direct Acting Antivirals by Payer Within the United States Healthcare System 1 2 3 Leah DB Carter & Mai T. Pho & Andrew Aronsohn Published online: 19 July 2017 Springer Science+Business Media, LLC 2017 Abstract Introduction Purpose of Review This review article charts the current land- scape of patient access to direct acting antivirals (DAAs) by As the leading cause of liver transplant and liver-related death payer within the United States healthcare system, including in the USA, hepatitis C (HCV) affects nearly 3.5 million Medicaid, Medicare, private/commercial health insurance, Americans and exceeds HIV and AIDS in number of deaths Department of Corrections, and the Department of Veteran’s globally. HCV elimination has been declared a health priority Affairs. Each payer is reviewed for barriers to access and by the World Health Organization (WHO), the United equity as well as analyzed with regard to cost. Nations, World Health Assembly, and the National Academy Recent Findings The advent of DAAs gives the promise not of Sciences [1, 2�� ]. Toward the aim of elimination, WHO just of cure but of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Hepatology Reports Springer Journals

The Landscape of Patient Access to Direct Acting Antivirals by Payer Within the United States Healthcare System

Loading next page...
 
/lp/springer_journal/the-landscape-of-patient-access-to-direct-acting-antivirals-by-payer-Gv2E6AIDoV
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Hepatology
eISSN
2195-9595
D.O.I.
10.1007/s11901-017-0359-5
Publisher site
See Article on Publisher Site

Abstract

Curr Hepatology Rep (2017) 16:192–197 DOI 10.1007/s11901-017-0359-5 HEPATITIS C (J AHN AND A ARONSOHN, SECTION EDITORS) The Landscape of Patient Access to Direct Acting Antivirals by Payer Within the United States Healthcare System 1 2 3 Leah DB Carter & Mai T. Pho & Andrew Aronsohn Published online: 19 July 2017 Springer Science+Business Media, LLC 2017 Abstract Introduction Purpose of Review This review article charts the current land- scape of patient access to direct acting antivirals (DAAs) by As the leading cause of liver transplant and liver-related death payer within the United States healthcare system, including in the USA, hepatitis C (HCV) affects nearly 3.5 million Medicaid, Medicare, private/commercial health insurance, Americans and exceeds HIV and AIDS in number of deaths Department of Corrections, and the Department of Veteran’s globally. HCV elimination has been declared a health priority Affairs. Each payer is reviewed for barriers to access and by the World Health Organization (WHO), the United equity as well as analyzed with regard to cost. Nations, World Health Assembly, and the National Academy Recent Findings The advent of DAAs gives the promise not of Sciences [1, 2�� ]. Toward the aim of elimination, WHO just of cure but of

Journal

Current Hepatology ReportsSpringer Journals

Published: Jul 19, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off